Lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed continuously in combination with osimertinib for EGFRmut non-small cell lung cancer: Initial phase Ib results

Category Primary study
JournalAnnals of Oncology
Year 2019
This article has no abstract
Epistemonikos ID: 0828509af904a484b1d9fb4be7429ad2f29424d8
First added on: Feb 11, 2025